In inoperable metastatic parathyroid carcinoma, persistently elevated PTH drives refractory hypercalcemia — the primary cause of morbidity and mortality in this setting. The clinical challenge is achieving durable control when initial systemic agents have not sustained it.
Inoperable metastatic parathyroid carcinoma with PTH-driven hypercalcemia. The primary treatment goal is controlling hypercalcemia, as it is the main determinant of outcomes in this population.
The preceding regimen used systemic calcium-lowering agents — mitramycin, plicamycin, gallium nitrate, intravenous bisphosphonates, and calcitonin in combination with glucocorticoid — as the primary means of controlling serum calcium and PTH.
That line's goals of sustained lowering of serum calcium and PTH levels were not durably achieved; results remained transient. This failure condition is the trigger for the present protocol.
Goals: reduction of PTH level and amelioration of intractable hypercalcemia.
DOI: 10.1007/s11864-011-0171-3
The primary treatment goal for inoperable metastatic parathyroid carcinoma is controlling PTH-driven hypercalcemia as it is the main cause of morbidity and mortality.
Ethanol ablation by ultrasound guided percutaneous injection of 98% ethanol into parathyroid tumor tissue can directly reduce PTH level and ameliorate intractable hypercalcemia.
Some inoperable distant metastatic lesions, such as intrahepatic and intrapulmonary lesions, are anatomically accessible by interventional radiologists and thus can be ablated transcutaneously with radiofrequency (RFA) or transcatheter arterial embolization (TAE).
Experimental immunotherapy has been successfully attempted in two inoperable metastatic parathyroid carcinoma cases.
This therapeutic approach requires the induction of adaptive immunity with PTH protein fragments.